Moss, 7 May 2021
Gentian Diagnostics ASA (the "Company") is pleased to announce that it has today
submitted an application for admission to trading on Oslo Børs by transfer of
its current admission to trading on Euronext Growth operated by Oslo Børs.
Subject to Oslo Børs' approval of the Company's admission application and
satisfaction of any conditions for admission to trading set by Oslo Børs, the
Company expects that the first day of trading of the Company's shares on Oslo
Børs will be in the end for June 2021.
For further information, please contact:
Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
More information:
Access the news on Oslo Bors NewsWeb site